الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
The survey of IVF clinics demonstrates that PGD is an established technology and medical procedure. Seventy-four percent of IVF clinics are offering PGD and PGD occurs in 4%–6% of all IVF cycles. Many provide PGD for more controversial indications such as sex selection. Although there is support among all IVF clinics for strong professional guidelines on PGD practice.
There have been several recent public calls for more thorough data collection in the United States about PGD, data that could help determine what oversight of PGD would be most appropriate
Internationally, some PGD data have been collected by ESHRE, but only 8% of US IVF–PGD clinics participate in ESHRE’s PGD data collection. The Genetics and Public Policy Center has been working closely with ASRM and PGDIS to develop a database to collect information about all PGD performed in the United States.
Detailed longitudinal research will help patients make better informed decisions and will help professionals develop appropriate guidelines and standards for PGD.
Although new indications are emerging for PGD, it is likely to remain a small part of reproductive practice for some time to come. Most new indications serve legitimate medical purposes, such as screening for single gene mutations for late onset disorders or susceptibility to cancer. There is also ethical support for using PGD to assure that a child is an HLA match with an existing child.
More controversial is the use of PGD to select gender or other non-medical traits. As with medical uses, the acceptability of non-medical screening will depend upon the interests served and the effects of using PGD for those purposes.
Speculations about potential future non-medical uses should not restrict new uses of PGD which are otherwise ethically acceptable PGD is increasingly available for aneuploidy in low prognosis IVF patients and for single gene mutations that cause genetic disease, susceptibility to cancer, and late onset disorders.
If PGD is acceptable to prevent offspring with serious genetic disease, then these additional uses should be acceptable as well.
There is also ethical support for using PGD to assure that a child is an HLA match with an existing child. More controversial is the use of PGD for gender selection, particularly for the first child. Equally controversial would be its use to screen embryos for hearing, sexual orientation, and other nonmedical traits—uses that are now highly speculative. Careful ethical analysis and open public debate is essential if new uses of PGD are to become acceptable methods for having children.